A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients

Introduction Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life settin...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neurology Vol. 271; no. 9; pp. 6209 - 6219
Main Authors:	Pane, Chiara, Di Stefano, Vincenzo, Cuomo, Nunzia, Sarnataro, Alessio, Vinciguerra, Claudia, Bevilacqua, Liliana, Brighina, Filippo, Rini, Nicasio, Puorro, Giorgia, Marsili, Angela, Garibaldi, Matteo, Fionda, Laura, Saccà, Francesco
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2024 Springer Nature B.V
Subjects:	Activities of Daily Living Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacology Complement Inactivating Agents - administration & dosage Complement Inactivating Agents - pharmacology Fc receptors Female Follow-Up Studies Humans Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Myasthenia gravis Myasthenia Gravis - drug therapy Neonates Neurology Neuromuscular junctions Neuroradiology Neurosciences Original Communication Patients Prednisone Receptors, Cholinergic - immunology Steroids Treatment Outcome Vaccination Innovative QMG Observational MG-ADL Seronegative Real-world evidence
ISSN:	0340-5354, 1432-1459, 1432-1459
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!